quinazolines has been researched along with ku 55933 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, J; Geng, MY; Meng, LH; Miao, ZH | 1 |
| Kinomura, A; Misumi, K; Miyata, Y; Okada, M; Sun, J; Tashiro, S | 1 |
1 review(s) available for quinazolines and ku 55933
| Article | Year |
|---|---|
Emerging cancer therapeutic opportunities target DNA-repair systems.
Topics: Animals; Antineoplastic Agents; Ataxia Telangiectasia Mutated Proteins; Cell Cycle Proteins; DNA Damage; DNA Repair; DNA-Binding Proteins; DNA, Neoplasm; Drug Resistance, Neoplasm; Guanine; Humans; Morpholines; Neoplasms; O(6)-Methylguanine-DNA Methyltransferase; Poly(ADP-ribose) Polymerases; Protein Serine-Threonine Kinases; Pyrones; Quinazolines; Signal Transduction; Tumor Suppressor Proteins | 2006 |
1 other study(ies) available for quinazolines and ku 55933
| Article | Year |
|---|---|
Enhanced gefitinib-induced repression of the epidermal growth factor receptor pathway by ataxia telangiectasia-mutated kinase inhibition in non-small-cell lung cancer cells.
Topics: Apoptosis; Ataxia Telangiectasia Mutated Proteins; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Morpholines; Mutation; Protein Kinase Inhibitors; Pyrones; Quinazolines; Signal Transduction | 2016 |